Wednesday, 16 Jan 2019

You are here

BMS Tyk 2 Inhibitor Benefits Psoriasis

The NEJM reports that an oral selecive Tyrosine kinase 2 (TYK2) inhibitor of TYK2 was shown to be superior to placebo in a 12 week trial in patients with active psoriasis.

In a 12 week, phase 2, double-blind trial, BMS-986165 (TYK2 inhibitor) or placebo was given to 267 patients with active moderate-to-severe psoriasis, who previously failed to respond to other targeted cytokine inhibitors.  Patients received wither 3 mg every other day, 3 mg daily, 3 mg twice daily, 6 mg twice daily, or 12 mg daily or to receive placebo. The primary end point was a 75% or greater reduction from baseline in the Psoriasis Area and Severity Index (PASI75) score at week 12.

At week 12, the PASI 75 response rates were:

  • PBO: 7% (3 of 45 patients)
  • 3 mg of BMS-986165 qod;  9% (4 of 44 patients) (P=0.49 vs. placebo)
  • 3 mg qd: 39% (17 of 44 patients) (P<0.001 vs. placebo)
  • 3 mg bid:  69% (31 of 45 patients) (P<0.001 vs. placebo)
  • 6 mg bid: 67% (30 of 45 patients) (P<0.001 vs. placebo)
  • 12 mg qd: 75% (33 of 44 patients) (P<0.001 vs. placebo).

Discontinuation rates were low, generally about 2% (ranging from 2-7%) and there were 3 serious adverse events in patients receiving the active drug, as well as one case of malignant melanoma 96 days after the start of treatment.

Targeted inhibition of TYK2 with the oral agent BMS-986165 at doses of 3 mg daily and higher resulted in significant clearing of psoriasis.

(Funded by Bristol-Myers Squibb; ClinicalTrials.gov number, NCT02931838.)

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Diet and Weight Loss Improves Psoriatic Arthritis

Short-term intervention with the very low energy diet (VLED) in psoriatic arthritis (PsA) with obesity (body mass index BMI ≥ 33 kg/m2) showed that weight loss was associated with significant positive benefits on weight and disease activity in joints, entheses and skin. 

H2H: Ixekizumab vs. Adalimumab in Psoriatic Arthritis

Lilly has issued an advanced press release on its SPIRIT-H2H trial, wherein ixekizumab (Taltz) was shown to be more effective than than adalimumab (Humira) in a 24 week psoriatic arthritis study.

SPIRIT-H2H study was designed as a large head-to-head (H2H) superiority study to assess the efficacy and safety of ixekizumab versus adalimumab active psoriatic arthritis (PsA) patients who are biologic naive.

Psoriatic Arthritis Does Not Add to Pregnancy Problems

When psoriatic arthritis (PsA) patients become pregnant, they do not have more infertility or adverse pregnancy outcomes compared to healthy controls.

This study is relevant as the average onset age of PsA ranges between the 4th-6th decades of life and therefore includes a period of child-bearing potential.

IL-23 Outduels IL-17 Inhibition in Psoriasis

Johnson & Johnson has announced the preliminary results of its phase 3 ECLIPSE study; a head-to-head trial wherein guselkumab (Tremfya; an IL-23 inhibitor) was compared to secukinumab (Cosentyx; an IL-17 inhibitor) in adults with moderate to severe plaque psoriasis.

New ACR/NPF Guidelines for Management of Psoriatic Arthritis

The American College of Rheumatology (ACR) and National Psoriasis Foundation (NPF) have released a joint treatment guideline for psoriatic arthritis (PsA) that provides evidence-based pharmacologic and non-pharmacologic recommendations and includes recommendations on other management issues including vaccinations, psoriatic spondylitis, enthesitis, and treatment in the presence of inflammatory bowel disease, diabetes, or serious infections.